Stance Capital’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
TP
Stance Capital's MRNA Position: Q2 2026 in Review
Stance Capital reduced its Moderna (MRNA) stake by 74% in Q2 2026, selling an estimated $21.7K and leaving 150 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #273.
Stance Capital first reported a position in MRNA in Q4 2024 and has held it in 4 quarters since. The position peaked at $28.9K in Q1 2026. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Stance Capital held 150 shares of Moderna worth $10.5K as of Q2 2026.
- Stance Capital sold 419 Moderna shares in Q2 2026, an estimated $21.7K.
- Moderna made up ﹤0.01% of Stance Capital's portfolio in Q2 2026, its #273 holding.
- Stance Capital first reported a position in Moderna in Q4 2024 and has held it in 4 quarters since.
- Stance Capital's Moderna position peaked at $28.9K in Q1 2026.
- 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Stance Capital's 13F filing for Q2 2026, filed 14 Aug 2026.